Company Research Report: Numinus Wellness Inc.

Company Overview

• Name: Numinus Wellness Inc.

• Mission: Numinus exists to help the world heal by addressing the global crisis in mental health through the power and promise of psychedelic medicine.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Payton Nyquvest, CEO

• Dr. Reid Robison, Chief Clinical Officer

• Dr. Evan Lewis, VP of Psychedelic Neurology

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Numinus is recognized for advancing psychedelic therapy, particularly through its clinical services, provider training, and participation in clinical trials.

Products and Services

Products/Services Offered

1. Clinics

• Description: Offers a variety of mental health treatments including traditional psychiatry, therapy, Ketamine Assisted Therapy, and Transcranial Magnetic Stimulation (TMS).

• Key Features:

• Multidisciplinary approach with a focus on human-centered care.

• Integration of alternative therapies for individuals unresponsive to conventional treatment.

2. Provider Training

• Description: Provides board-accredited psychedelic-assisted therapy training for licensed and non-licensed professionals.

• Key Features:

• Offers high-quality, engaging learning experiences.

• Training reflects values of evidence-based healing and innovation.

3. Clinical Trials

• Description: Engaged in research studies to refine therapies and foster breakthroughs in mental health treatments.

• Key Features:

• Focus on psychedelic-assisted therapies.

• Collaboration with leading organizations for expanded research opportunities.

Recent Developments

• New Products/Features:

• Introduction of experiential training opportunities for MDMA-Assisted Therapy practitioners, pending approval from Health Canada.

• Partnerships:

• Collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS) to develop education and training programs for MDMA-Assisted Therapy.

• Acquisitions:

• Acquisition of the Neurology Centre of Toronto, enhancing their capacity to treat neurological disorders with concurrent mental health challenges.

• Research and Conferences:

• Participation in various investor conferences to discuss advancements in safe, evidence-based psychedelic-assisted therapies.

• Submission of a U.S. provisional patent for a rapid production process for psychedelic extracts.

Conclusion

This report provides a comprehensive overview of Numinus Wellness Inc., highlighting its mission-driven approach to transform mental health care through psychedelic medicine, its diverse range of treatment options, and recent strategic activities to expand and strengthen its position in the mental health landscape. While some foundational details about the company remain unspecified, the available information underscores its commitment to evidence-based innovation and human-centered care.